Skip to main content

Advertisement

SpringerLink
Log in

Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

In 2011, a new pathological classification of lung adenocarcinoma was proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. The new criteria classify adenocarcinomas into eight subtypes according to their histological features. The criteria introduce a new concept of early stage lung cancer, consisting of adenocarcinoma in situ and minimally invasive adenocarcinoma, and categorize invasive adenocarcinomas by the predominant histological pattern. In addition to morphological differences among subtypes, the classification also considers the tumor behavior based on the genetic background within each subtype. We herein review the clinical impact of this new classification for chest surgeons based on the data from several recent validation studies from various institutions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46–52.

    Article  PubMed  Google Scholar 

  2. Nakamura H, Saji H. A worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today. 2014;44:1004–12.

    Article  PubMed  Google Scholar 

  3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Colby TV, Noguchi M, Henschke C, Vazquez MF, Geisinger K, Yokose T, et al. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink KH, Harris CC, editors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARCPress; 2004. p. 35–44.

    Google Scholar 

  5. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol. 2005;23:8396–405.

    Article  PubMed  Google Scholar 

  6. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844–52.

    Article  CAS  PubMed  Google Scholar 

  7. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992–1001.

    Article  CAS  PubMed  Google Scholar 

  8. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6:1496–504.

    Article  PubMed  Google Scholar 

  9. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653–64.

    Article  CAS  PubMed  Google Scholar 

  10. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30:1438–46.

    Article  PubMed  Google Scholar 

  11. Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014;146:633–43.

    Article  PubMed  Google Scholar 

  12. Gu J, Lu C, Guo J, Chen L, Chu Y, Ji Y, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol. 2013;107:474–80.

    Article  PubMed  Google Scholar 

  13. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients–based on a hospital study in China. Eur J Surg Oncol. 2013;39:1262–8.

    Article  CAS  PubMed  Google Scholar 

  14. Hung JJ, Jeng WJ, Chou TY, Hsu WH, Wu KJ, Huang BS, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258:1079–86.

    Article  PubMed  Google Scholar 

  15. Lee HJ, Kim YT, Kang CH, Zhao B, Tan Y, Schwartz LH, et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology. 2013;268:254–64.

    Article  PubMed  Google Scholar 

  16. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8:52–61.

    Article  CAS  PubMed  Google Scholar 

  17. Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371–6.

    Article  PubMed  Google Scholar 

  18. Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol. 2014;38:448–60.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Kawaguchi T, Matsumura A, Fukai S, Tamura A, Saito R, Zell JA, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol. 2010;5:1001–10.

    PubMed  Google Scholar 

  20. Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM. Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. Arch Pathol Lab Med. 2013;138:626–35.

    Article  PubMed  Google Scholar 

  21. Nitadori J, Bograd AJ, Kadota K, Sima CS, Rizk NP, Morales EA, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer. 2013;1(105):1212–20.

    Article  Google Scholar 

  22. Cha MJ, Lee HY, Lee KS, Jeong JY, Han J, Shim YM, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014;147:921–8.

    Article  PubMed  Google Scholar 

  23. Warth A, Cortis J, Fink L, Fisseler-Eckhoff A, Geddert H, Hager T, et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch. 2012;461:185–93.

    Article  PubMed  Google Scholar 

  24. Honda T, Kondo T, Murakami S, Saito H, Oshita F, Ito H, et al. Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification. Clin Radiol. 2012;2013(68):e21–6. doi:10.1016/j.crad.2012.09.002.

    Google Scholar 

  25. Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, Zabor EC, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol. 2012;19:3598–605.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Godoy MC, Naidich DP. Overview and strategic management of subsolid pulmonary nodules. J Thorac Imaging. 2012;27:240–8.

    Article  PubMed  Google Scholar 

  27. Nakamura H, Saji H, Ogata A, Saijo T, Okada S, Kato H. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection. Lung Cancer. 2004;44:61–8.

    Article  PubMed  Google Scholar 

  28. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, et al. Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;129:1226–31.

    Article  PubMed  Google Scholar 

  29. Yoshida J, Nagai K, Yokose T, Nishimura M, Kakinuma R, Ohmatsu H, et al. Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg. 2005;129:991–6.

    Article  PubMed  Google Scholar 

  30. Nakamura H, Hirata T, Taguchi M, Kitamura H. Ground-glass opacities showing an adenoma-to-carcinoma sequence in the lung. Gen Thorac Cardiovasc Surg. 2008;56:421–3.

    Article  PubMed  Google Scholar 

  31. Kadota K, Yeh YC, Sima CS, Rusch VW, Moreira AL, Adusumilli PS, et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol. 2014;27:690–700.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Westaway DD, Toon CW, Farzin M, Sioson L, Watson N, Brady PW, et al. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology. 2013;45:553–8.

    Article  PubMed  Google Scholar 

  33. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

    Article  CAS  PubMed  Google Scholar 

  34. Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

    Article  CAS  PubMed  Google Scholar 

  35. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738–41.

    CAS  PubMed  Google Scholar 

  36. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561–5.

    Article  CAS  PubMed  Google Scholar 

  37. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.

    Article  CAS  PubMed  Google Scholar 

  38. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31:1097–104.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study. Cancer. 2014;120:1471–81.

    Article  CAS  PubMed  Google Scholar 

  40. Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, et al. Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas. J Thorac Oncol. 2014;9:760–8.

    Article  CAS  PubMed  Google Scholar 

  41. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol. 2014;232:121–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Goss GD, O’Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31:3320–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54–9.

    Article  CAS  PubMed  Google Scholar 

  44. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, et al. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PloS One. 2013;8:e76999. doi:10.1371/journal.pone.0076999.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013;79:8–13.

    Article  PubMed  Google Scholar 

  49. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol. 2013;30:645. doi:10.1007/s12032-013-0645-1.

    Article  PubMed  Google Scholar 

  50. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) Classification With Prognosis and EGFR Mutation in Lung Adenocarcinoma. Ann Thorac Surg. 2014;98:453–8.

    Article  PubMed  Google Scholar 

  51. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013;8:461–8.

    Article  PubMed  Google Scholar 

  52. Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer. 2013;81:1–10.

    Article  PubMed  Google Scholar 

  53. Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, et al. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg. 2013;96:962–8.

    Article  PubMed  Google Scholar 

  54. Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakayama E, Takahashi T, et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol. 2012;19(Suppl 3):S347–54.

    Article  PubMed  Google Scholar 

  55. D’Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;7:1815–22.

    Article  PubMed  Google Scholar 

  56. Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin. 2013;139:1691–700.

    Article  CAS  Google Scholar 

  57. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012;18:1947–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Sim HJ, Choi SH, Chae EJ, Kim HR, Kim YH, Kim DK, et al. Surgical management of pulmonary adenocarcinoma presenting as a pure ground-glass nodule. Eur J Cardiothorac Surg 2014 Feb 23 [Epub ahead of print].

  59. Hu HD, Wan MY, Xu CH, Zhan P, Zou J, Zhang QQ, et al. Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance. J Thorac Dis. 2013;5:841–6.

    PubMed Central  PubMed  Google Scholar 

  60. Araki K, Kidokoro Y, Hosoya K, Wakahara M, Matsuoka Y, Takagi Y, et al. Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor. Anticancer Res. 2014;34:3153–6.

    PubMed  Google Scholar 

  61. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiov Surg. 2011;141:662–70.

    Article  PubMed  Google Scholar 

  62. Shapiro M, Kadakia S, Lim J, Breglio A, Wisnivesky JP, Kaufman A, et al. Lobe-specific mediastinal nodal dissection is sufficient during lobectomy by video-assisted thoracic surgery or thoracotomy for early-stage lung cancer. Chest. 2013;144:1615–21.

    Article  PubMed  Google Scholar 

  63. Nakao M, Yoshida J, Goto K, Ishii G, Kawase A, Aokage K, et al. Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. J Thorac Oncol. 2012;7:1563–6.

    Article  PubMed  Google Scholar 

  64. Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.

    Article  PubMed  Google Scholar 

  65. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137:668–84.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Woo T, Okudela K, Mitsui H, Tajiri M, Yamamoto T, Rino Y, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int. 2012;62:785–91.

    Article  CAS  PubMed  Google Scholar 

  67. Campos-Parra AD, Aviles A, Contreras-Reyes S, Rojas-Marin CE, Sanchez-Reyes R, Borbolla-Escoboza RJ, et al. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur Respir J. 2014;43:1439–47.

    Article  PubMed  Google Scholar 

  68. Yoshino I. Substantial risk affects the stage-dependent outcomes of cisplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer. Surg Today. 2014;44:302–6.

    Article  CAS  PubMed  Google Scholar 

  69. Yasuda M, Nagashima A, Haro A, Saitoh G. Treatment of the postoperative recurrence of lung cancer in octogenarians. Surg Today. 2014;44:1626–32.

    Article  PubMed  Google Scholar 

  70. Uramoto H, Shimokawa H, Hanagiri T, Ichiki Y, Tanaka F. Factors predicting the surgical outcome in patients with T3/4 lung cancer. Surg Today. 2014. doi:10.1007/s00595-014-0861-0.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kanagawa, Kawasaki, 216-8511, Japan

    Haruhiko Nakamura

  2. Department of Pathology, St. Marianna University School of Medicine, Kanagawa, Kawasaki, Japan

    Masayuki Takagi

Authors
  1. Haruhiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haruhiko Nakamura.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, H., Takagi, M. Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons. Surg Today 45, 1341–1351 (2015). https://doi.org/10.1007/s00595-014-1089-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-014-1089-8

Keywords

Search

Navigation